Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
CD19-specific chimeric antigen receptor (CAR)-modified T cells have antitumor activity in B cell malignancies, but factors that affect toxicity and efficacy have been difficult to define because of differences in lymphodepletion and heterogeneity of CAR-T cells administered to individual patients. We conducted a clinical trial in which CD19 CAR-T cells were manufactured from defined T cell subsets and administered in a 1:1 CD4(+)/CD8(+) ratio of CAR-T cells to 32 adults with relapsed and/or refractory B cell non-Hodgkin's lymphoma after cyclophosphamide (Cy)-based lymphodepletion chemotherapy with or without fludarabine (Flu). Patients who received Cy/Flu lymphodepletion had increased CAR-T cell expansion and persistence, and higher response rates [50% complete remission (CR), 72% overall response rate (ORR)] than patients who received Cy-based lymphodepletion without Flu (8% CR, 50% ORR). The CR rate in patients treated with Cy/Flu at the maximally tolerated dose was 64% (82% ORR; n = 11). Cy/Flu minimized the effects of an immune response to the murine single-chain variable fragment component of the CAR, which limited CAR-T cell expansion and clinical efficacy in patients who received Cy-based lymphodepletion without Flu. Severe cytokine release syndrome (sCRS) and grade ≥3 neurotoxicity were observed in 13 and 28% of all patients, respectively. Serum biomarkers, one day after CAR-T cell infusion, correlated with subsequent sCRS and neurotoxicity. Immunotherapy with CD19 CAR-T cells in a defined CD4(+)/CD8(+) ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progression-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“prolonged in vivo persistence of CAR-T cells has been correlated with the depth and durability of clinical responses [32, 36].”
From Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium (2025) · cites this paper as [36]
In the citing paper
“It is also known that lymphodepletion and the establishment of an optimal homeostatic cytokine environment is critical for robust CAR T-cell expansion and function.4,44,45”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112 · cited 3×
“We observed that treatment with the same lymphodepletion and CD19 CAR-T cell immunotherapy regimen resulted in lower CR rates in NHL and chronic lymphocytic leukemia (CLL) patients compared to B-ALL patients (1, 25).”
BackgroundResultSelf-citation
Research works printed but not linked: 2
- Gordis L Epidemiology 4 Philadelphia Saunders 2008
- Yeh ST Using trapezoidal rule for the area under a curve calculation Proceedings of the Twenty-Seventh Annual SAS User Group International (SUGI) Conference. Paper 229–27 2002
Cited by
Items 701–800 of 999
CAR T-cell therapy: a potential treatment strategy for pediatric midline gliomas
Das, A. K., Sinha, M., Singh, S. K., Chaudhary, A., Boro, A. K., Agrawal, M., Bhardwaj, S., Kishore, S., & Kumari, K. (2024) · Acta Neurologica Belgica · doi:10.1007/s13760-024-02519-8 · Cited by 12
“These models simulated DIPG's diffusely invading histopathology [53, 54].”
Ansell, S. M., Caligaris‐Cappio, F., & Maloney, D. G. (2017) · Hematological Oncology · doi:10.1002/hon.2408 · Cited by 9
“T cell product containing CD4: CD8 cells in a defined 1:1 ratio in 32 patients with NHL.14 In this phase I/II trial, we observed that the dose of CAR‐”
MethodVeto cells for safer nonmyeloablative haploidentical HSCT and CAR T cell therapy
Reisner, Y., & Or‐Geva, N. (2019) · Seminars in Hematology · doi:10.1053/j.seminhematol.2019.03.003 · Cited by 9
Zhao, J., Wu, M., Li, Z., Su, S., Wen, Y., Zhang, L., & Li, Y. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04020-7 · Cited by 11
“Among the 7 evaluable patients with aggressive B-NHL, 4 patients (57”
MethodInfluentialLong, M., Mims, A. S., & Li, Z. (2022) · Immunological Investigations · doi:10.1080/08820139.2022.2131569 · Cited by 10
“…to be subpar comparing to CD19 chimeric antigen receptor (CAR) T cells (Abramson et al. 2016; Brentjens et al. 2013; Gardner et al. 2016; Grupp et al. 2015; Lee et al. 2015; Lee et al. 2016; Locke et al. 2017; Neelapu et al. 2017; Schuster et al. 2015; Turtle et al. 2016a; Turtle et al. 2016b).”
BackgroundEngineered T Cell Therapies from a Drug Development Viewpoint
Chen, F., Fraietta, J. A., June, C. H., Xu, Z., Melenhorst, J. J., & Lacey, S. F. (2018) · Engineering · doi:10.1016/j.eng.2018.11.010 · Cited by 9
“the chimeric protein in most patients could be attributed to cyclophosphamide/fludarabine lymphodepletion treatment [79].”
BackgroundPinturaud, M., Vasseur, M., & Odou, P. (2018) · Bulletin du Cancer · doi:10.1016/s0007-4551(19)30051-7 · Cited by 11
Hung, L. V. M., Ngo, H. T., & Pham, P. V. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_522 · Cited by 12
Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma
Hsieh, E. M., & Rouce, R. H. (2020) · Hematology · doi:10.1182/hematology.2020000133 · Cited by 10
CAR T-Cell therapies in lymphoma: current landscape, ongoing investigations, and future directions
Haydu, J. E., & Abramson, J. S. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.39 · Cited by 10
A historical overview of amebiasis.
Imperato, P. J. (1981) · PubMed · Cited by 16
Yeung, C. C. S., Woolston, D. W., Wu, V., Voutsinas, J. M., Basom, R., Davis, C., Hirayama, A. V. V., & Naresh, K. N. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14068 · Cited by 10
Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy
Ogusuku, I. E. Y., Herbel, V., Lennartz, S., Brandes, C., Argiro, E. M., Fabian, C., Hauck, C., Hoogstraten, C., Veld, S. A. J., Hageman, L., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101224 · Cited by 11
The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management
Anurogo, D., Luthfiana, D., Anripa, N., Fauziah, A. I., Soleha, M., Rahmah, L., Ratnawati, H., Wargasetia, T. L., Pratiwi, S. E., Siregar, R. N., et al. (2024) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2024.034 · Cited by 9
Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells
Masmoudi, D., Vialaret, J., Hirtz, C., & Alix‐Panabières, C. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13665 · Cited by 11
Zhou, L., Zhao, S., Luo, J., Rao, M., Yang, S., Wang, H., & Tang, L. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s473068 · Cited by 9
Tseng, H., Dholaria, B., Cranert, S. A., Richter, M., Marquez, K., Cho, B. S., Bacong, A., McArthur, K., Eskew, J. D., McCaigue, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65267-0 · Cited by 10
“This observation aligns with previous clinical reports that patients receiving Cy/Flu had higher ORR compared to patients receiving Cy alone 30 .”
Rewiring T Cell Metabolism to Enhance CAR T Cell Function in Solid Tumor Microenvironments
Song, A. W., & Song, X. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121520 · Cited by 9
“The advent of CAR T cell therapy has marked a significant advancement in oncology, achieving remarkable success in the treatment of refractory B cell hematologic malignancies [1–7].”
Shah, M., Rajha, E., Dinardo, C. D., Muckey, E., Wierda, W. G., & Yeung, S. J. (2019) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.07.015 · Cited by 8
The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review
Saleh, O. M., Albakri, K. A., Alabdallat, Y. J., Dajani, M., & Gazzar, W. B. E. (2021) · Biomarkers · doi:10.1080/1354750x.2021.2016973 · Cited by 10
“It signals the shift of prostate epithelial cells from a highly proliferative to a more differentiated state, and it may be used to identify a subpopulation of cells that are vulnerable to transformation during prostate carcinogenesis (Uzgare et al. 2004).”
BackgroundNeurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention
Zhang, B., Li, X., Yin, T., Qin, D., Chen, Y., Ma, Q., Shu, P., & Wang, Y. (2022) · Journal of Oncology · doi:10.1155/2022/4259205 · Cited by 12
Lymphodepleting Conditioning Regimens
Mohty, M., & Minnema, M. C. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0_25 · Cited by 8
Filioglou, D., Husnain, M., Khurana, S., Simpson, R. J., & Katsanis, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1329850 · Cited by 8
“The addition of Flu to CY appears to be bene fi cial, improving the expansion and the persistence of CAR-T-cells (6, 26).”
BackgroundGupta, S., Kohorst, M. A., & Alkhateeb, H. B. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14132 · Cited by 8
“8,13,45 The ELIANA trial used either fludarabine + cyclophosphamide (98”
MethodFrame, D. G., Geer, M. J., Kasha, S., Markstrom, D., Scappaticci, G. B., Feeney, T., Hayduk, A., Mansoor, H. M., Oberfeld, A., D’Antonio, H., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1403145 · Cited by 8
Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma
Gong, I. Y., Tran, D., Saibil, S. D., Laister, R. C., & Kuruvilla, J. G. (2024) · HemaSphere · doi:10.1002/hem3.130 · Cited by 10
A dynamical systems perspective on chimeric antigen receptor T-cell dosing
Toor, A. A., Chesney, A., Zweit, J., Reed, J., & Hashmi, S. K. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0329-8 · Cited by 7
New Immunotherapies in Oncology Treatment and Their Side Effect Profiles
Sriratana, P., & Norton, J. A. (2018) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2018.04.170387 · Cited by 8
Ivics, Z. (2020) · Gene Therapy · doi:10.1038/s41434-020-0138-8 · Cited by 8
Emerging CAR landscape for cancer immunotherapy
Lim, F., & Ang, S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114051 · Cited by 8
An overview of multiplexed analyses of CAR T-cell therapies: insights and potential
DePriest, B. P., Vieira, N., Bidgoli, A., & Paczesny, S. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1992276 · Cited by 9
“10), interferon gamma (IFN-γ), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein 1-beta (MIP1β) and tumor necrosis factor-alpha (TNF-α) [5,16,19,106,120,124], though many new biomarker studies”
BackgroundInfluentialClinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions
Schroeder, B., Jess, J., Sankaran, H., & Shah, N. N. (2022) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000723 · Cited by 10
“Lymphodepletion regimen Use of fludarabine with cyclophosphamide [37,41,57]”
BackgroundKoski, J., Jahan, F., Luostarinen, A., Schenkwein, D., Ylä‐Herttuala, S., Göös, H., Monzó, H. J., Ojala, P. M., Maliniemi, P., & Korhonen, M. O. (2022) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2022.1049580 · Cited by 10
“, 2018), diffuse large cell B-cell lymphoma (Turtle et al., 2016; Neelapu et al., 2017; Locke et al., 2019; Lamure et al., 2021) and multiple myeloma (Raje et al.”
BackgroundAnagnostou, T., & Ansell, S. M. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0720-8 · Cited by 9
Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond
Desai, S. H., & Ansell, S. M. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1885667 · Cited by 10
Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review
George, L. L., Deshpande, S., Cortese, M. J., Kendall, E. K., Chattaraj, A., Shah, Z., Zhao, J., & Anwer, F. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.06.003 · Cited by 8
CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies
Mi, J., Xu, J., Zhou, J., Zhao, W., Zhu, C. H., Melenhorst, J. J., & Chen, S. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0904-z · Cited by 8
“immune rejection may limit efficacy of CAR T-cell response, leading to relapse after initial infusion and resistance to reinfusion [21,65].”
BackgroundSu, M., Dey, A., Maddah, E., Mugundu, G. M., & Singh, A. P. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13259 · Cited by 9
Bates, S. M., Evans, K. V., Delsing, L., Wong, R., Cornish, G. H., & Bahjat, M. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104239 · Cited by 11
Liu, Y., Duan, Y., Du, Z., Lu, J., Liu, C., Li, L., Tian, M., Li, L., Yao, R., Ouyang, C., et al. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00683-y · Cited by 10
Wang, M., Komanduri, K. V., Datta, D., Patel, A. R., Whitaker, B. I., Belov, A. A., Rubin, B., Vashist, R., Rodríguez-Monguió, R., Cinar, P., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016375 · Cited by 9
Or‐Geva, N., Gidron-Budovsky, R., Radomir, L., Edelstein, Y., Singh, A. K., Muskatel, R. S., Ophir, E., Bachar-Lustig, E., & Reisner, Y. (2017) · Leukemia · doi:10.1038/leu.2017.332 · Cited by 7
Individual cell‐based modeling of tumor cell plasticity‐induced immune escape after CAR‐T therapy
Zhang, C., Shao, C., Jiao, X., Bai, Y. Y., Li, M., Shi, H., Lei, J., & Zhong, X. (2021) · Computational and Systems Oncology · doi:10.1002/cso2.1029 · Cited by 12
CAR-T Cell Therapy: Advances in Kidney-Related Diseases
Wu, L., Feng, Y., Huang, Y., Feng, J., Hu, Y., & Huang, H. (2024) · Kidney Diseases · doi:10.1159/000536194 · Cited by 7
A CAR-T response prediction model for r/r B-NHL patients based on a T cell subset nomogram
Zhang, X., Sun, R., Zhang, M., Zhao, Y., Cao, X., Guo, R., Zhang, Y., Liu, X., Lyu, C., & Zhao, M. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03618-w · Cited by 8
Porter, L. H., Harrison, S., Risbridger, G. P., Lister, N. L., & Taylor, R. A. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106571 · Cited by 10
“Clinical trials have demonstrated improved CAR T cell expansion and clinical responses using this approach for haematological malignancies [61,62], and studies are underway to determine whether these benefits are also seen in solid tumors.”
BackgroundFu, W., Dai, Y., Ma, T., Wei, J., Chen, H., & Xu, S. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.5897 · Cited by 8
“Currently, the development of novel drugs for AD treatment has focused on ways of decreasing Aβ levels; however the results of clinical trials have not been promising (16,17).”
Hunter, B. D., Chen, Y., & Jacobson, C. A. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.03.005 · Cited by 7
Management of Cytokine Release Syndrome
Varadarajan, I., Kindwall‐Keller, T. L., & Lee, D. W. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00005-6 · Cited by 11
REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY
Bacher, U., Brechbühl, S., Jeker, B., & Pabst, T. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2021.012 · Cited by 6
“Currently, CAR-T cell therapy is further evaluated for patients with r/r MM in clinical studies and will soon be in commercial use.(3,6,9,18-33) The majority of the clinical CAR-T cell trials in multiple myeloma target the B-cell maturation antigen (BCMA), which shows predominant expression on myeloma and normal plasm…”
BackgroundA second CD19 CAR T-cell infusion: yes or no?
Casucci, M., & Ciceri, F. (2021) · Blood · doi:10.1182/blood.2020009206 · Cited by 7
Ren, L., Li, L., Zhang, L., Li, X., Fu, X., Wang, X., Wu, J., Sun, Z., Feng, X., Chang, Y., et al. (2021) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-021-01433-w · Cited by 9
“CAR-T is associated with potentially fatal toxicities, including cytokine release syndrome and neurotoxicity making it ineligible for comorbid or older RR DLBCL with complications [13, 14].”
BackgroundClinical experience of CAR T cells for B cell acute lymphoblastic leukemia
Fabrizio, V. A., & Curran, K. J. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101305 · Cited by 7
A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma
Ying, Z., He, T., Jin, S., et al. (2022) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2022.01.05 · Cited by 7
“Patients with CD19-positive r/r B-NHL who previously received at least one line of treatment were recruited (Supplementary Table S1).”
BackgroundInfluentialOvercoming resistance to anti‐CD19 CAR T‐cell therapy in B‐cell malignancies
Yang, X., Wei, J., & Zhou, J. (2022) · Hematological Oncology · doi:10.1002/hon.3036 · Cited by 7
“The role of CD19 antigen escape is less defined in B‐NHL compared with B‐ALL.(20) The”
BackgroundFoster, M. R., Negash, Y., Eberhardt, L., Bryan, W. W., Schultz, K., Wang, X., Xu, Y., & George, B. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.10.006 · Cited by 7
Green, S. G., & Schultz, L. M. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01404-6 · Cited by 7
Chimeric antigen receptor‐based immunotherapy in breast cancer: Recent progress in China
Yu, T., Lu, Y., Fang, J., Jiang, X., Lu, Y., Zheng, J., Xi, S., Shen, H., & Fu, P. (2023) · Cancer · doi:10.1002/cncr.35096 · Cited by 10
“9 Tumor heterogeneity of high mutational level in TA production is considered the major challenge in CAR ‐ based therapy.”
BackgroundLiu, Y., Zhao, C., Gao, L., Yang, H., He, R., & Gao, C. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.216 · Cited by 7
Analysis of the function of MAGE-A in esophageal carcinoma by bioinformatics
Chen, X., Cai, S., Wang, L., Zhang, X., Li, W., & Cao, X. (2019) · Medicine · doi:10.1097/md.0000000000015774 · Cited by 8
“Car-T is another significant clinical progress in cancer immunotherapy and has been used in certain hematological oncologies.([3,20,21]) Nevertheless, the effect of”
BackgroundChimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy.
Kravets, V. G., Zhang, Y., & Sun, H. (2017) · PubMed · Cited by 13
Immune and Cell Therapy in Non-Hodgkin Lymphoma
Merryman, R. W., Houot, R., Armand, P. A., & Jacobson, C. A. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000445 · Cited by 8
Saifi, O., Kharfan‐Dabaja, M. A., Zeidan, Y. H., Peterson, J., Rule, W. G., Lester, S. C., & Hoppe, B. S. (2020) · International Journal of Particle Therapy · doi:10.14338/ijpt-20-00004.1 · Cited by 7
“CAR T-cell therapy brings a new array of toxicities, and several studies have described these side effects [25, 26].”
BackgroundLin, X., Dai, Z., Tasiheng, Y., Zhang, R., Wang, R., Dong, J., Chen, Y., Ma, M., Zou, X., Yan, Y., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167346 · Cited by 6
Li, R., Grosskopf, A. K., Joslyn, L. R., Stefanich, E. G., & Shivva, V. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01017-w · Cited by 6
“Some studies have also shown correlation between TCT dose and CRS severity (109), while other studies report no such correlation (78).”
InfluentialJordana-Urriza, L., Serrano, G., Camara-Peña, S., Calleja-Cervantes, M. E., Martín‐Úriz, P. S., Zabaleta, A., Oliver‐Caldés, A., Español‐Rego, M., Alignani, D., Lozano, T., et al. (2026) · Blood Neoplasia · doi:10.1016/j.bneo.2026.100203 · Cited by 6
Taheri, S. (2022) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.390259 · Cited by 6
A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers
Olifirenko, V., & Barlev, N. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126595 · Cited by 8
“For example, traditional chemotherapy agents, such as cyclophosphamide and fludarabine, are known to reduce the population of immunosuppressive cells in solid tumors [53,54].”
BackgroundCAR, CRS und Neurotoxizität: schwere Komplikationen der Immuntherapie
Prinz, J., d’Hargues, Y., Gödel, P., Shimabukuro‐Vornhagen, A., Kochanek, M., & Böll, B. (2018) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-018-0518-7 · Cited by 6
Ivics, Z., Amberger, M., Zahn, T. R., & Hildt, E. (2020) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-020-03223-7 · Cited by 6
Yang, C., Lei, W., Xie, H.-Q., Wu, G., Wei, J., Liang, A., & Qian, W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s280535 · Cited by 6
“It is reported that in vivo expansion and persistence of CAR-T cells seem to be associated with remission in B-cell malignancies.(10,19) In the present study, peak expansion of CAR-T cells in the blood occurred at 10–12 days.”
BackgroundMethodHIV-specific CAR T cells return to the clinic
Peterson, C. W. (2021) · Journal of Clinical Investigation · doi:10.1172/jci153204 · Cited by 8
Luque-Paz, D., Sesques, P., Wallet, F., Bachy, E., & Ader, F. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2101448 · Cited by 6
Rouce, R. H., & Heslop, H. E. (2017) · Blood · doi:10.1182/blood-2017-04-779983 · Cited by 5
Hay, K. A., & Turtle, C. J. (2018) · Immunotherapy · doi:10.2217/imt-2017-0162 · Cited by 7
Thibodeaux, S. R., & Milone, M. C. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2016.258988 · Cited by 8
Li, Q., Mu, J., Yuan, J., Yang, Z., Wang, J., & Deng, Q. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s277146 · Cited by 6
Peters, T., Mühlgrabner, V., Cárdenas, R. M.-H. V., Platzer, R., Göhring, J., Plach, A., Plach, A., Höhrhan, M., Perez, I. D., Gonçalves, V. D. R., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj4632 · Cited by 9
Is there a place for engineered immune cell therapies in autoimmune diseases?
Perico, L., Casiraghi, F., Benigni, A., & Remuzzi, G. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.01.011 · Cited by 5
Abramson, J. S., Kamdar, M. K., Liu, F. F., Crotta, A., Previtali, A., Klijn, S. L., Wang, P., Zhang, Y., Bonner, A., & Lunning, M. A. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2532674 · Cited by 5
“…NR, not reached; pFS, progression-free survival; saaipi, secondary age-adjusted international prognostic index; SoC, standard of care; SpD, sum of the product of perpendicular diameters. total and relative doses of CD8 + and CD4 + CAR + T cells may also contribute to reduced toxicity [25,26].”
Montero, J. C. S., Gonzalez, A. C. C., Martín-Aguilar, L., & Mancebo, J. (2020) · Medicina Intensiva · doi:10.1016/j.medin.2020.06.014 · Cited by 5
Ahern, K., Pham, J., Sanderson, R., Farias, M. C. D., & Walsh, K. (2023) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.13210 · Cited by 5
Applications and Opportunities for Immune Cell CAR Engineering in Comparative Oncology
Rotolo, A., & Atherton, M. J. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3690 · Cited by 9
Liu, X., Ma, B., & Zhao, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1342162 · Cited by 8
Advances in research on factors affecting chimeric antigen receptor T‐cell efficacy
Zhou, D., Zhu, X., & Xiao, Y. (2024) · Cancer Medicine · doi:10.1002/cam4.7375 · Cited by 6
“40 Furthermore, studies conducted on patients with B-cell lymphomas 107–109 and B-ALL 110,111 showed enhanced treatment responses when lymphodepletion chemotherapy was administered before CAR T-cell infusion.”
ResultImmuno-Oncology in Urothelial Carcinoma: Who or What Will Ultimately Sit on the Iron Throne?
Ramos, J., & Yu, E. Y. (2017) · Immunotherapy · doi:10.2217/imt-2017-0109 · Cited by 5
Dalal, A.-R., Homsy, S., & Balkhi, M. Y. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.244 · Cited by 5
Gene Modified T Cell Therapies for Hematological Malignancies
Mock, U., Delhove, J. M. K. M., & Qasim, W. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.005 · Cited by 5
Novel approaches to promote CAR T-cell function in solid tumors
Hull, C., & Maher, J. F. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1614164 · Cited by 5
Redirecting T cells to treat solid pediatric cancers
Rauwolf, K. K., & Rössig, C. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09821-5 · Cited by 5
“In vivo lymphodepletion using both fludarabine and cyclophosphamide has been found to be a key prerequisite for optimal CAR T cell activity even in hematological malignancies [129], but this alone is insufficient in solid tumors.”
BackgroundA Systematic Review of the Efforts and Hindrances of Modeling and Simulation of CAR T-cell Therapy
Nukala, U., Messan, M. R., Yogurtcu, O. N., Wang, X., & Yang, H. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2101.05359 · Cited by 5
Arena, G., & Chiarle, R. (2025) · Cancers · doi:10.3390/cancers17213453 · Cited by 6
“Turtle et al. demonstrated that the addition of Fludarabine to a Cyclophosphamide (Cy/Flu) conditioning regimen was linked to improved proliferation and persistence of CD19-CAR T cells in patients with r/r B-NHL and better clinical outcomes [27,28].”
Snyder, A. J., Garrison, S. M., Kluesner, M. G., Nutt, W. S., Shasha, C., Ho, T. T. G., Marsh, S. A., Linde, M. H., Wu, F., Meyer, L. K., et al. (2026) · Science Immunology · doi:10.1126/sciimmunol.adw7685 · Cited by 6
In vivo CAR-T therapy: from molecular design to precision delivery
Li, H., Wen, W., Zhao, X., & Liang, G. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04232-5 · Cited by 7
Chen, P., Raghunandan, R., Morrow, J. S., & Katz, S. G. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.04.002 · Cited by 6
European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring
Angelis, B. D., D'Amore, M. L., Lecot, P., Neininger, K., Lorrain, M., Gambotti, L., Dreuillet, C., Courcault, E., Chatterjee, S., Delgado, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1567582 · Cited by 5
Roman, C. M., Sakemura, R. L., Jin, F., Khadka, R. H., Adada, M. M., Siegler, E. L., Johnson, A. J., & Kenderian, S. S. (2023) · Journal of Visualized Experiments · doi:10.3791/64535 · Cited by 4
Post-mortem neuropathologic examination of a 6-case series of CAR T-cell treated patients
Vidal‐Robau, N., Caballero, G., Archilla, I., Ladino, A., Fernández, S., Ortiz‐Maldonado, V., Rovira, M., Gómez‐Hernando, M., Delgado, J., Suárez‐Lledó, M., et al. (2022) · Free Neuropathology · doi:10.17879/freeneuropathology-2022-4365 · Cited by 5
“Here we present the neuropathological findings of 6 deceased patients, 3 women and 3 men, who received a CD19- (5) and BCMA- (1) targeted CAR T-cell therapy.”
BackgroundChimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma
Hasanali, Z. S., Razzo, B. M., Susanibar-Adaniya, S. P., Garfall, A. L., Stadtmauer, E. A., & Cohen, A. D. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.004 · Cited by 5
Cho, E., An, M. H., Lee, Y. S., Ryu, E. J., Lee, Y. R., Park, S. Y., Kim, Y. J., Lee, C. H., Oh, D., Kim, M. S., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109256 · Cited by 8
Metadata
- Authors
- Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., Soma, L., Wood, B., Li, D., Heimfeld, S., Riddell, S. R., & Maloney, D. G.
- Affiliations
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Juno Therapeutics (United States) (US)
- Corresponding author
- Turtle, Cameron J.
- Riddell, Stanley R.
- Maloney, David G.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-09-07
- Volume
- 8
- Issue
- 355
- Pages
- 355ra116-355ra116
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5045301
- OpenAlex
- W2509364267
- Semantic Scholar
- af93b35d4d1ed32f3de2e434b4049004928a60bc
- Cited by
- 1,016
- References
- 38
- Citations by year
- 2026: 37 · 2025: 60 · 2024: 101 · 2023: 78 · 2022: 113 · 2021: 120 · 2020: 153 · 2019: 139 · 2018: 121 · 2017: 85 · 2016: 6
- FWCI
- 63.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01 CA136551)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK56465)
- NCI (P30 CA15704)
- Life Science Discovery Fund
- Bezos Family Foundation
- Juno Therapeutics
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, non-Hodgkin lymphoma, B-cell lymphoma, CD4/CD8 ratio, lymphocyte depletion, cyclophosphamide, fludarabine, cytokine release syndrome, neurotoxicity, serum biomarkers, CAR T cell persistence, relapsed/refractory lymphoma
- MeSH terms
- Adult, Aged, Cyclophosphamide, Female, Humans, Immunotherapy, Lymphocyte Depletion, Lymphoma, Non-Hodgkin, Male, Middle Aged, Receptors, Antigen, T-Cell, Syndrome, Biomarkers, Tumor, Vidarabine, CD4-Positive T-Lymphocytes, Lymphocyte Subsets, Treatment Outcome, CD8-Positive T-Lymphocytes, Transgenes, Cell Proliferation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.